Study of seroprevalance of Toxoplasma gondii, Rubella virus and Cytomegalovirus (ToRC) infections in antenatal women presented with bad obstetric history and comparative evaluation of Nanoplex ToRCH screen ELISA kit with VIDAS

Susmitha Simgamsetty, Padmaja Yarlagadda, Bindu Madhav Yenigalla, Ramesh Babu Myneni

Abstract


Background: Infections caused by Toxoplasma gondii, Rubella virus and Cytomegalovirus are major causes of Bad Obstetric History (BOH). Cause of BOH may be genetic, hormonal, abnormal maternal immune response, and maternal infection. Women affected with any of these diseases during pregnancy are at high risk for miscarriage, stillbirth, or for a child with serious birth defects and/or illness and also a hazard to attending staff nurses.

Methods: A total 96 serum samples were collected from antenatal women with BOH attending the out-patient services of department of gynaecology at NRI general hospital, Chinakakani, Guntur district, Andhra Pradesh. Serum samples were obtained and were subjected to screening for Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies of Toxopalsma gondii, Rubella Virus and CMV infections by VIDAS (bioMerieux, France) and Nanoplex ToRCH Screen kit [Lilac Medicare (P) Ltd, Maharastra, India].  

Results: Majority of cases with BOH were found in females aged 18-23 years (25, 52.08%) followed by 24-29 years (18, 37.5%). Congenital anomalies and other complications were found to be more in age group 18-23 years followed by 24-29 years. The disease prevalence as studied with respect to IgM antibodies was found to be 31.25% for Cytomegalovirus Infections, 23.96% for Toxoplasma gondii, 21.88% for Rubella virus infections. The overall agreement in the Sensitivity, Specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) between VIDAS and Nanoplex ToRCH Screen kit for the detection of specific IgM and IgG antibodies in our study was excellent with sensitivity ranging from 90.91%-96.00% and specificity ranging from 89.47%-95.59% for the detection of IgM& IgG antibodies. The discrepancies were relatively less with 8.3% for CMV IgM, 6.2% for CMV IgG, 5.20% for Rubella IgM, 6.25% for Rubella IgG, 6.25% for Toxo IgM and 5.20% for Toxo IgG.

Conclusion: Nanoplex ToRCH Screen Kit is a cheap, cost effective, efficient and innovative alternate for the diagnosis of ToRCH infections. As the technology is new, it needs to be further explored bring out various multiplex kits for diagnosing other infectious diseases.

 


Keywords


BOH, TORCH, VIDAS, Nanoplex ToRCH Screen Kit

Full Text:

PDF

References


Sabreen AA. Kamal, Ruqaya MJ. Awadh, Ali HM. Al-Marzoqi. Genetic study of ToRCH Infections in women with bad obstetric history: multiplex polymerase chain reaction for detection of common pathogens and agents of congenital infections. J Biol Agriculture Healthcare. 2013;3(18):49-53.

Turbadkar D, Mathur M, Rele M. Seroprevelence of torch infection in bad obstetric history. Indian J Med Microbiol. 2003;21:108-10.

Sharma P, Gupta T, Ganguly NK, Mahajan RC, Malla N. Increasing Toxoplasma seropositivity in women with bad obstetric history and in new-borns. Natl Med J. 1997;10:65-6.

Seth P, Manjunath N, Balaya S. Rubella infection: the Indian scene. Rev Infect Dis. 1985;7(Suppl 1):S64-7.

Peekam C. Congenital infections in the United Kingdom before 1970; the prevaccine era. Rev Infect Dis. 1985;7(Suppl 1):S11.

Stagno S, Pass RF, Cloud G, Britt WJ, Henderson RE, Walton PD, et al. Primary Cytomegalovirus infection in pregnancy: incidence, transmission to fetus, and clinical outcome. JAMA. 1986;256:1904-8.

Padmavathy M, Mangala Gowri, Malini J, Umapathi BL, Navaneeth BV, Mohit Bhatia, et al. Seroprevalence of ToRCH infections and adverse reproductive outcome in current pregnancy with bad obstetric history. J Clin Biomed Sci. 2013;3(2):62-71.

Young AB, Reid D, Grist NR. Is Cytomegalovirus a serious hazard to female hospital staff? Lancet. 1983;321(8331):975-6.

Bernard Weber, Marisol Badiel, Yanet Alvarez-Otero, Philippe Thulliez, José G. Montoya. Comparative evaluation of AxSYM, VIDAS and VIDIA toxoplasmosis reagent performance in a high seroprevalence Latin American country. Sientia Medica (Porto Alegre). 2010;20(1):27-34.

Hopson DK, Niles AC, Murray PR. Comparison of the Vitek immunodiagnostic assay system with three immunoassay systems for detection of cytomegalovirus-specific immunoglobulin G. J Clin Microbiol. 1992;30(11):2893-5.

Pelloux H, Ciapia P, Goullier-Fleuret A, Ambroise-Thomas P. Evaluation dd system Vidas pour le diagnostic serologique de la toxoplasmose. Ann Biol Clin.1993;5:875-8.

Dave J, Balfour AH, Perkin J. Evaluation of the VIDAS toxo competition assay for the detection of antibodies specific to Toxoplasma gondii in human sera. Sero diagn immunother Infect Disease. 1994;6:41-5.

Sadik MS, Fatima H, Jamil K, Patil C. Study of TORCH profile in patients with bad obstetric history. Biol Med. 2012;4(2):95-101.

Binnicker MJ, Jespersen DJ, Harring JA. Multiplex detection of IgM and IgG class antibodies to Toxoplasma gondii, Rubella virus, and Cytomegalovirus using a Novel Multiplex flow immunoassay. Clin Vaccine Immunol. 2010;17(11):1734-8.

Kumari N, Morris N, Dutta R. Is screening of ToRCH worthwhile in women with bad obstetric history: an observation from Eastern Nepal? J Health Popul Nutr. 2011;29(1):77-80.

Shashi C, Usha A, Aruna A. Prevalence of IgM antibodies to Toxoplasma, Rubella and Cytomegalovirus infections during pregnancy. JK Sci. 2004;6(4):190-3.